| Inhibition of Pro-apoptotic BAX by a noncanonical interaction mechanism LA Barclay, TE Wales, TP Garner, F Wachter, S Lee, RM Guerra, ... Molecular cell 57 (5), 873-886, 2015 | 150 | 2015 |
| Paclitaxel reduces axonal Bclw to initiate IP3R1-dependent axon degeneration SE Pease-Raissi, MF Pazyra-Murphy, Y Li, F Wachter, Y Fukuda, ... Neuron 96 (2), 373-386. e6, 2017 | 100 | 2017 |
| Cell cycle-arrested tumor cells exhibit increased sensitivity towards TRAIL-induced apoptosis H Ehrhardt, F Wachter, M Grunert, I Jeremias Cell death & disease 4 (6), e661-e661, 2013 | 60 | 2013 |
| MDM2 and MDM4 are therapeutic vulnerabilities in malignant rhabdoid tumors TP Howard, TE Arnoff, MR Song, AO Giacomelli, X Wang, AL Hong, ... Cancer research 79 (9), 2404-2414, 2019 | 54 | 2019 |
| Mechanistic validation of a clinical lead stapled peptide that reactivates p53 by dual HDM2 and HDMX targeting F Wachter, AM Morgan, M Godes, R Mourtada, GH Bird, LD Walensky Oncogene 36 (15), 2184-2190, 2017 | 52 | 2017 |
| Allosteric sensitization of proapoptotic BAX JR Pritz, F Wachter, S Lee, J Luccarelli, TE Wales, DT Cohen, P Coote, ... Nature chemical biology 13 (9), 961-967, 2017 | 48 | 2017 |
| Cellular uptake and ultrastructural localization underlie the pro-apoptotic activity of a hydrocarbon-stapled BIM BH3 peptide AL Edwards, F Wachter, M Lammert, AJ Huhn, J Luccarelli, GH Bird, ... ACS chemical biology 10 (9), 2149-2157, 2015 | 44 | 2015 |
| Optimized anti–tumor effects of anthracyclines plus Vinca alkaloids using a novel, mechanism-based application schedule H Ehrhardt, D Schrembs, C Moritz, F Wachter, S Haldar, U Graubner, ... Blood, The Journal of the American Society of Hematology 118 (23), 6123-6131, 2011 | 37 | 2011 |
| Enhanced anti‐tumour effects of V inca alkaloids given separately from cytostatic therapies H Ehrhardt, L Pannert, S Pfeiffer, F Wachter, E Amtmann, I Jeremias British journal of pharmacology 168 (7), 1558-1569, 2013 | 26 | 2013 |
| NOXA as critical mediator for drug combinations in polychemotherapy H Ehrhardt, I Höfig, F Wachter, P Obexer, S Fulda, N Terziyska, I Jeremias Cell death & disease 3 (6), e327-e327, 2012 | 26 | 2012 |
| Important role of caspase-8 for chemosensitivity of ALL cells H Ehrhardt, F Wachter, M Maurer, K Stahnke, I Jeremias Clinical Cancer Research 17 (24), 7605-7613, 2011 | 26 | 2011 |
| Impact of the p53 status of tumor cells on extrinsic and intrinsic apoptosis signaling F Wachter, M Grunert, C Blaj, DM Weinstock, I Jeremias, H Ehrhardt Cell Communication and Signaling 11, 1-10, 2013 | 16 | 2013 |
| Chemical Specification of E3 Ubiquitin Ligase Engagement by Cysteine-Reactive Chemistry RC Sarott, I You, YD Li, ST Toenjes, KA Donovan, P Seo, M Ordonez, ... Journal of the American Chemical Society 145 (40), 21937-21944, 2023 | 7 | 2023 |
| TRAIL preferentially affects cell cycle-arrested tumor cells including stem-and progenitor cells from patients with acute lymphoblastic leukemia H Ehrhardt, CC Alves, F Wachter, I Jeremias Blood 120 (21), 1879, 2012 | 5 | 2012 |
| Molecular characterization of inflammatory tumors facilitates initiation of effective therapy F Wachter, A Al-Ibraheemi, MC Trissal, M Hollowell, SG DuBois, ... Pediatrics 148 (6), e2021050990, 2021 | 4 | 2021 |
| Activation of DNA damage response by antitumor therapy counteracts the activity of vinca alkaloids H Ehrhardt, S Pfeiffer, D Schrembs, F Wachter, M Grunert, I Jeremias Anticancer Research 33 (12), 5273-5287, 2013 | 3 | 2013 |
| Rapid next-generation sequencing aids in diagnosis of transient abnormal myelopoiesis in a phenotypically normal newborn R Aziz-Bose, F Wachter, R Chiarle, NI Lindeman, AS Kim, BA Degar, ... Blood Advances 6 (9), 2893-2896, 2022 | 2 | 2022 |
| Autoimmune hemolytic anemia complicated by parvovirus infection F Wachter, NM Archer Blood 137 (8), 1130, 2021 | 2 | 2021 |
| The current landscape: Allogeneic hematopoietic stem cell transplant for acute lymphoblastic leukemia S Prockop, F Wachter Best Practice & Research Clinical Haematology 36 (3), 101485, 2023 | 1 | 2023 |
| Comment on: Clinical, pathologic, and molecular features of inflammatory myofibroblastic tumors in children and adolescents: ROS1-fusion inflammatory myofibroblastic tumor … F Wachter, KA Janeway Pediatric Blood & Cancer 70 (2), e29907-e29907, 2022 | 1 | 2022 |
